1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Obesity Partnering 2010-2015

Obesity Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
Obesity Partnering 2009-2014 report provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies.


Description

Obesity Partnering 2009-2014 report provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies.

•Trends in obesity partnering deals
•Top obesity deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type

Obesity Partnering 2009-2014 provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of obesity partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obesity technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 130 links to online copies of actual obesity deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of obesity partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in obesity partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading obesity deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of obesity partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of obesity technologies and products.

Report scope

Obesity Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to obesity trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

•Trends in obesity dealmaking in the biopharma industry since 2009
•Access to summary headline, upfront, milestone and royalty data
•The leading obesity deals by value since 2009

In Obesity Partnering 2009-2014, the available deals are listed by:

•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Benefits

Obesity Partnering 2009-2014 provides the reader with the following key benefits:


•In-depth understanding of obesity deal trends since 2009
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 130 actual obesity deals entered into by the world’s biopharma companies since 2009
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Keywords

obesity, public health, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Obesity Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in obesity partnering

2.1. Introduction
2.2. Obesity partnering over the years
2.3. Big pharma obesity dealmaking activity
2.4. Big biotech obesity dealmaking activity
2.5. Most active obesity dealmakers
2.6. Obesity partnering by deal type
2.7. Obesity partnering industry sector
2.8. Obesity partnering by stage of development
2.9. Obesity partnering by technology type
2.10. Disclosed financial deal terms for obesity
2.10.1 Obesity headline values
2.10.2 Obesity upfront payments
2.10.3 Obesity milestone payments
2.10.4 Obesity royalty rates

Chapter 3 - Leading obesity deals

3.1. Introduction
3.2. Top obesity deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Obesity partnering since 2009
Figure 2: Big pharma - top 50 - obesity deals 2009 to 2014
Figure 3: Big pharma obesity deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - obesity deals 2009 to 2014
Figure 5: Big biotech obesity deal frequency - 2009 to 2014
Figure 6: Obesity dealmaking activity- 2009 to 2014
Figure 7: Obesity partnering by deal type since 2009
Figure 8: Obesity partnering by industry sector since 2009
Figure 9: Obesity partnering by stage of development since 2009
Figure 10: Obesity partnering by technology type since 2009
Figure 11: Obesity deals with a headline value
Figure 12: Obesity deals with upfront payment values
Figure 13: Obesity deals with milestone payments
Figure 14: Obesity deals with royalty rates, %
Figure 15: Top obesity deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Obesity Treatment Market Size & Forecast, By Drugs, By Surgery & Devices And Trend Analysis To 2024

Obesity Treatment Market Size & Forecast, By Drugs, By Surgery & Devices And Trend Analysis To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The global obesity treatment market is expected to reach USD 15.6 billion by 2024, according to a new report by Grand View Research, Inc. Upward trend in sedentary lifestyles, physical inactivity, and ...

Global Intragastric Balloons Market - Strategic Assessment and Forecast Till 2021

Global Intragastric Balloons Market - Strategic Assessment and Forecast Till 2021

  • $ 2995
  • Industry report
  • October 2016
  • by Beige Market Intelligence

The global intragastric balloons market is expected to grow at a CAGR of more than 7.01% till 2021. Global Intragastric Balloons Market - Strategic Assessment and Forecast till 2021 market research report ...

Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline ...

Obesity-api Insights, 2016

November 2016 $ 1250

Download Unlimited Documents from Trusted Public Sources

Cardiovascular Disease Statistics in the US

  • December 2016
    171 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Public Health Industry in the UK

  • December 2016
    156 pages
  • Public Health  

    Neurological Di...  

    Hospital  

  • United Kingdom  

View report >

Public Health Markets in the UK

  • December 2016
    45 pages
  • Public Health  

    Obesity  

    Food  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Obesity

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.